10000|10000|Public
5|$|Aspirin {{is used as}} an {{anti-inflammatory}} {{agent for}} both acute and long-term inflammation, as well as <b>for</b> <b>treatment</b> <b>of</b> inflammatory diseases, such as rheumatoid arthritis.|$|E
5|$|Evidence of the {{effectiveness}} of recompression therapy utilizing oxygen was first shown by Yarbrough and Behnke, and has since become the standard of care <b>for</b> <b>treatment</b> <b>of</b> DCS.|$|E
5|$|Subcision {{is useful}} <b>for</b> <b>treatment</b> <b>of</b> {{superficial}} atrophic acne scars and {{involves the use}} of a small needle to loosen the fibrotic adhesions that result in the depressed appearance of the scar.|$|E
40|$|The {{potential}} of a large variety of new compounds and new strategies <b>for</b> the <b>treatment</b> <b>of</b> virtually all major virus infections has been addressed. This includes, <b>for</b> the <b>treatment</b> <b>of</b> HIV infections, virus adsorption inhibitors (cosalane derivatives, cyanovirin-N), co-receptor antagonists (TAK- 779, AMD 3100), viral fusion inhibitors (pentafuside T- 20, betulinic acid derivatives), viral uncoating inhibitors (azodicarbonamide), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs: emtricitabine, amdoxovir, dOTC, d 4 TMP prodrugs, tenofovir disoproxil fumarate), non-nucleoside reverse transcriptase inhibitors (NNRTIs: thiocarboxanilide UC- 781, capravirine, SJ- 3366, DPC 083, TMC 125 /R 165335), integrase inhibitors (diketo acids), transcription inhibitors (temacrazine, flavopiridol), protease inhibitors (atazanavir, mozenavir, tipranavir); <b>for</b> the <b>treatment</b> <b>of</b> RSV and paramyxovirus infections, viral fusion inhibitors (R 170591, VP- 14637, NMS 03); <b>for</b> the <b>treatment</b> <b>of</b> picornavirus infections, viral uncoating inhibitors (pleconaril); <b>for</b> the <b>treatment</b> <b>of</b> pesti- (hepaci-, flavi-) virus infections, RNA replicase inhibitors (VP- 32947); <b>for</b> the <b>treatment</b> <b>of</b> herpesvirus (HSV, VZV, CMV) infections, DNA polymerase inhibitors (A- 5021, L- and D-cyclohexenylguanine); <b>for</b> the <b>treatment</b> <b>of</b> VZV infections, bicyclic furopyrimidine analogues; <b>for</b> the <b>treatment</b> <b>of</b> CMV infections, fomivirsen; <b>for</b> the <b>treatment</b> <b>of</b> DNA virus infections at large (papilloma-, polyoma-, herpes-, adeno- and poxvirus infections), cidofovir; <b>for</b> the <b>treatment</b> <b>of</b> influenza, neuraminidase inhibitors (zanamivir, oseltamivir, RWJ- 270201); <b>for</b> the <b>treatment</b> <b>of</b> HBV infections, adefovir dipivoxil; <b>for</b> the <b>treatment</b> <b>of</b> HBV and HCV infections, N-glycosylation inhibitors (N-nonyl-deoxynojirimycin); and, finally, IMP dehydrogenase inhibitors and S-adenosylhomocysteine hydrolase inhibitors, <b>for</b> the <b>treatment</b> <b>of</b> various virus infections, including hemorrhagic fever virus infections. status: publishe...|$|R
50|$|The company's {{clinical}} drug candidates include sotagliflozin (LX4211) <b>for</b> the <b>treatment</b> <b>of</b> type 2 diabetes; LX1033 <b>for</b> the <b>treatment</b> <b>of</b> {{irritable bowel syndrome}} and other gastrointestinal disorders; telotristat ethyl (LX1032) <b>for</b> the <b>treatment</b> <b>of</b> the symptoms associated with carcinoid syndrome; and LX2931 <b>for</b> the <b>treatment</b> <b>of</b> autoimmune diseases, such as rheumatoid arthritis.|$|R
40|$|Foremost {{among the}} newly {{described}} antiviral agents {{that may be}} developed into drugs are, <b>for</b> the <b>treatment</b> <b>of</b> human papilloma virus (HPV) infections, cPrPMEDAP; <b>for</b> the <b>treatment</b> <b>of</b> herpes simplex virus (HSV) infections, BAY 57 - 1293; <b>for</b> the <b>treatment</b> <b>of</b> varicella-zoster virus (VZV) infections, FV- 100 (prodrug of Cf 1743); <b>for</b> the <b>treatment</b> <b>of</b> cytomegalovirus (CMV) infections, maribavir; <b>for</b> the <b>treatment</b> <b>of</b> poxvirus infections, ST- 246; <b>for</b> the <b>treatment</b> <b>of</b> hepatitis B virus (HBV) infections, tenofovir disoproxil fumarate (TDF) (which in the meantime has already been approved in the EU); <b>for</b> the <b>treatment</b> <b>of</b> various DNA virus infections, the hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) prodrugs <b>of</b> cidofovir; <b>for</b> the <b>treatment</b> <b>of</b> orthomyxovirus infections (i. e., influenza), peramivir; <b>for</b> the <b>treatment</b> <b>of</b> hepacivirus infections (i. e., hepatitis C), the protease inhibitors telaprevir and boceprevir, the nucleoside RNA replicase inhibitors (NRRIs) PSI- 6130 and R 1479, and various non-nucleoside RNA replicase inhibitors (NNRRIs); <b>for</b> the <b>treatment</b> <b>of</b> human immunodeficiency virus (HIV) infections, integrase inhibitors (INIs) such as elvitegravir, nucleoside reverse transcriptase inhibitors (NRTIs) such as apricitabine, non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as rilpivirine and dapivirine; and <b>for</b> the <b>treatment</b> <b>of</b> both HCV and HIV infections, cyclosporin A derivatives such as the non-immunosuppressive Debio- 025. status: publishe...|$|R
5|$|Therapeutic {{recompression}} is {{a medical}} procedure <b>for</b> <b>treatment</b> <b>of</b> decompression sickness, and is followed by decompression, usually to a relatively conservative schedule.|$|E
5|$|A {{chelating}} agent is a molecule {{with at least}} two negatively charged groups that allow it to form complexes with metal ions with multiple positive charges, such as lead. The chelate that is thus formed is nontoxic and can be excreted in the urine, initially at up to 50 times the normal rate. The {{chelating agent}}s used <b>for</b> <b>treatment</b> <b>of</b> lead poisoning are edetate disodium calcium (CaNa2EDTA), dimercaprol (BAL), which are injected, and succimer and d-penicillamine, which are administered orally.|$|E
5|$|According to Leutnant zur See Hans-Otto Brodt, their {{commanding}} officer Korvettenkapitän Heinz Bucholz and another 50 {{men of the}} crew of 64, went down with the ship. The prisoners {{were sent to the}} sick bay <b>for</b> <b>treatment</b> <b>of</b> shock and exposure and supplied with fresh clothing that had been provided by the Red Cross. Until Omaha put in at Bahia, on 15 February, where they debarked and were transported to Recife, the Germans were placed under armed guard.|$|E
50|$|The eight {{biotechnology}} {{products are}} available in four core therapeutic areas: neurology <b>for</b> the <b>treatment</b> <b>of</b> relapsing forms of multiple sclerosis, reproductive health <b>for</b> <b>treatments</b> <b>of</b> infertility, dermatology, where Serono has launched biologics in Europe for moderate-to-severe psoriasis, andgrowth and metabolism <b>for</b> <b>treatments</b> <b>for</b> HIV-associated wasting and growth deficiencies.|$|R
50|$|The Company {{offers its}} major {{products}} under three categories: Artemether series, consisting of artemether injections, capsules, and tablets <b>for</b> the <b>treatment</b> <b>of</b> subtertian malaria; Sanqi series, <b>for</b> the <b>treatment</b> <b>of</b> cardiovascular and cerebrovascular diseases, and Gastrodine series, <b>for</b> the <b>treatment</b> <b>of</b> headache and neuralgia.|$|R
50|$|It is {{indicated}} <b>for</b> the <b>treatment</b> <b>of</b> coronary artery disease. It {{has also been}} used <b>for</b> the <b>treatment</b> <b>of</b> asthma.|$|R
5|$|Although {{antidepressants}} with anxiolytic properties {{have been}} introduced, {{and there is}} increasing awareness of the adverse effects of benzodiazepines, prescriptions for short-term anxiety relief have not significantly dropped. <b>For</b> <b>treatment</b> <b>of</b> insomnia, benzodiazepines are now less popular than nonbenzodiazepines, which include zolpidem, zaleplon and eszopiclone. Nonbenzodiazepines are molecularly distinct, but nonetheless, they work on the same benzodiazepine receptors and produce similar sedative effects.|$|E
5|$|An early {{estimate}} by the Small Business Administration put total {{damage in}} Gilroy {{at twice the}} amount of what was seen in Hollister. Ten people were brought to Hazel Hawkins Memorial Hospital in Hollister <b>for</b> <b>treatment</b> <b>of</b> lacerations, a cardiac problem, and anxiety. In Gilroy, the Wheeler Hospital saw six similar cases and a patient with a fractured hip. Most of those that sought care (including four that were transported by ambulance) were treated and released, but six were admitted.|$|E
5|$|Clindamycin {{preparations}} for oral administration include capsules (containing clindamycin hydrochloride) and oral suspensions (containing clindamycin palmitate hydrochloride). Oral suspension is not favored for administration of clindamycin to children, {{due to its}} extremely foul taste and odor. Clindamycin is formulated in a vaginal cream and as vaginal ovules <b>for</b> <b>treatment</b> <b>of</b> bacterial vaginosis. It is also available for topical administration in gel form, as a lotion, and in a foam delivery system (each containing clindamycin phosphate) and a solution in ethanol (containing clindamycin hydrochloride) and is used primarily as a prescription acne treatment.|$|E
40|$|Second editionGuidelines <b>for</b> the <b>treatment</b> <b>of</b> malaria Second editionGuidelines <b>for</b> the <b>treatment</b> <b>of</b> malaria – 2 nd edition WHO Library Cataloguing-in-Publication Data Guidelines <b>for</b> the <b>treatment</b> <b>of</b> malaria [...] 2 nd edition. 1. Malaria – drug therapy. 2. Malaria – diagnosis. 3. Antimalarials – {{administration}} an...|$|R
5000|$|Vismodegib (Erivedge), a smoothened {{receptor}} inhibitor <b>for</b> the <b>treatment</b> <b>of</b> basal-cell carcinoma, {{being investigated}} <b>for</b> the <b>treatment</b> <b>of</b> {{other types of}} cancer ...|$|R
50|$|Today CIM {{produces}} biopharmaceutical products, such as anti-CD3 {{monoclonal antibody}} <b>for</b> the <b>treatment</b> <b>of</b> patients with organ transplant rejection, human recombinant erythropoietin <b>for</b> the <b>treatment</b> <b>of</b> anemia, {{granulocyte colony-stimulating factor}} <b>for</b> the <b>treatment</b> <b>of</b> neutropenia, and a humanized monoclonal antibody that recognizes the epidermal growth factor receptor <b>for</b> cancer <b>treatment,</b> {{as well as other}} monoclonal antibodies for tumor imaging.|$|R
5|$|Ford {{suffered}} two minor strokes at the 2000 Republican National Convention, {{but made}} a quick recovery after being admitted to Hahnemann University Hospital. In January 2006, he spent 11 days at the Eisenhower Medical Center near his residence at Rancho Mirage, California, <b>for</b> <b>treatment</b> <b>of</b> pneumonia. On April 23, 2006, President George W. Bush visited Ford {{at his home in}} Rancho Mirage for a little over an hour. This was Ford's last public appearance and produced the last known public photos, video footage, and voice recording.|$|E
5|$|In December 2012 Clinton {{was hospitalized}} {{for a few}} days <b>for</b> <b>treatment</b> <b>of</b> a blood clot in her right {{transverse}} venous sinus. Her doctors had discovered the clot during a follow-up examination for a concussion she had sustained when she fainted and fell nearly three weeks earlier, as a result of severe dehydration from a viral intestinal ailment acquired during a trip to Europe. The clot, which caused no immediate neurological injury, was treated with anticoagulant medication and her doctors have said she has made a full recovery.|$|E
5|$|In July, the Federal Bureau of Prisons {{rejected}} {{a request by}} the Army to transfer Manning from the USDB to a civilian facility <b>for</b> <b>treatment</b> <b>of</b> her gender dysphoria. Instead, the Army kept Manning in military custody {{and said it would}} begin rudimentary gender treatment, which could include allowing her to wear female undergarments and possibly receive hormone treatments.|$|E
25|$|Thrombolytic {{drugs are}} {{contraindicated}} <b>for</b> the <b>treatment</b> <b>of</b> unstable angina and NSTEMI and <b>for</b> the <b>treatment</b> <b>of</b> individuals {{with evidence of}} cardiogenic shock.|$|R
50|$|<b>For</b> the <b>treatment</b> <b>of</b> {{pyelonephritis}} during pregnancy, and <b>for</b> the <b>treatment</b> <b>of</b> pyelonephritis {{caused by}} gram-positive organisms, amoxicillin or amoxicillin-clavulanate potassium is preferred.|$|R
50|$|Thrombolytic {{drugs are}} {{contraindicated}} <b>for</b> the <b>treatment</b> <b>of</b> unstable angina and NSTEMI and <b>for</b> the <b>treatment</b> <b>of</b> individuals {{with evidence of}} cardiogenic shock.|$|R
5|$|In a {{systematic}} analysis of 19 studies with 207 cases, there was an 87% improvement in overall symptom rate and 90% cure rate <b>for</b> <b>treatment</b> <b>of</b> papilloedema. Major complications only occurred in 3/207 patients (1.4%). In the largest single series of transverse sinus stenting there was an 11% rate of recurrence after one stent, requiring further stenting.|$|E
5|$|Ipilimumab blocks {{signaling}} {{through a}} receptor on T cells known as CTLA-4 which dampens down the immune system. It {{has been approved}} by the U.S. Food and Drug Administration (FDA) <b>for</b> <b>treatment</b> <b>of</b> melanoma and is undergoing clinical trials for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).|$|E
5|$|Linear {{particle}} accelerators generate electron beams <b>for</b> <b>treatment</b> <b>of</b> superficial tumors in radiation therapy. Electron therapy can treat such skin lesions as basal-cell carcinomas because an electron beam only penetrates {{to a limited}} depth before being absorbed, typically up to 5cm for electron energies in the range 5–20MeV. An electron beam {{can be used to}} supplement the treatment of areas that have been irradiated by X-rays.|$|E
40|$|Current {{management}} of age-related macular degeneration (AMD) {{is directed at}} intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors <b>for</b> the <b>treatment</b> <b>of</b> wet AMD and supplementation with oral antioxidants <b>for</b> the <b>treatment</b> <b>of</b> dry AMD. In this article, we will review recent clinical trials <b>for</b> the <b>treatment</b> <b>of</b> dry and wet AMD...|$|R
5000|$|On November 7, 2012, BioSpecifics {{announced}} [...] Auxilium's {{submission of}} a License Application to the FDA for Xiaflex <b>for</b> the potential <b>treatment</b> <b>of</b> Peyronie's disease, {{an excess of}} inelastic collagen causing penile curvature deformity. The FDA approved Xiaflex <b>for</b> the <b>treatment</b> <b>of</b> Peyronie’s disease in December 2013. Following this, Xiapex gained EU approval <b>for</b> the <b>treatment</b> <b>of</b> Peyronie’s disease in February 2015, making it {{the first and only}} biologic therapy indicated <b>for</b> the <b>treatment</b> <b>of</b> Peyronie's disease. Auxilium has also reported additional trials for potential use of Xiaflex are underway <b>for</b> the <b>treatment</b> <b>of</b> frozen shoulder, cellulite reductions and both human and canine lipomas.|$|R
25|$|Stimulants are {{the most}} {{effective}} medications available <b>for</b> the <b>treatment</b> <b>of</b> ADHD. Seven different formulations of stimulants have {{been approved by the}} U.S. Food and Drug Administration (FDA) <b>for</b> the <b>treatment</b> <b>of</b> ADHD: four amphetamine-based formulations, two methylphenidate-based formulations, and dextromethamphetamine hydrochloride. Atomoxetine, guanfacine and clonidine are the only non-controlled, non-stimulant FDA approved drugs <b>for</b> the <b>treatment</b> <b>of</b> ADHD.|$|R
5|$|Morpholinos are in {{development}} as pharmaceutical therapeutics targeted against pathogenic organisms such as bacteria or viruses and genetic diseases. The Morpholino drug eteplirsen from Sarepta Therapeutics received accelerated {{approval from the}} US Food and Drug Administration <b>for</b> <b>treatment</b> <b>of</b> some mutations causing Duchenne muscular dystrophy.|$|E
5|$|Recompression on air {{was shown}} to be an {{effective}} treatment for minor DCS symptoms by Keays in 1909. Evidence of the effectiveness of recompression therapy utilizing oxygen was first shown by Yarbrough and Behnke, and has since become the standard of care <b>for</b> <b>treatment</b> <b>of</b> DCS. Recompression is normally carried out in a recompression chamber. At a dive site, a riskier alternative is in-water recompression.|$|E
5|$|Siddiqui's first {{breakthrough}} in research {{came when he}} successfully isolated an antiarrhythmic agent in 1931 from the roots of Rauwolfia serpentina. He named the newly discovered chemical compound as Ajmaline, after his mentor Hakim Ajmal Khan {{who was one of}} the illustrious practitioners of Unani system of medicine in South Asia. Later on, Siddiqui also extracted other alkaloids from Rauwolfia serpentina that included Ajmalinine, Ajmalicine (C21H24N2O3), Isoajmaline, Neoajmaline, Serpentine and Serpentinine. Many of these are still used worldwide <b>for</b> <b>treatment</b> <b>of</b> mental disorders and cardiovascular ailments, especially as antiarrhythmic agents in Brugada syndrome.|$|E
50|$|DFINE {{developed}} products <b>for</b> the <b>treatment</b> <b>of</b> spinal diseases using a radiofrequency platform. The platform covers two procedures, one <b>for</b> the <b>treatment</b> <b>of</b> {{vertebral compression}} fractures and one <b>for</b> palliative <b>treatment</b> <b>of</b> metastatic spinal tumors. Both have received clearance from the United States Food and Drug Administration and CE Mark approval for use within the European Economic Area.|$|R
50|$|Top1 is a {{validated}} target <b>for</b> the <b>treatment</b> <b>of</b> human cancers. Camptothecins {{are among}} the most effective anticancer agents recently introduced into clinical practice. In this regard, the camptothecin derivative topotecan (Hycamtin) is approved by the U.S. FDA <b>for</b> the <b>treatment</b> <b>of</b> ovarian and lung cancer. Another camptothecin derivative irinotecan (CPT11) is approved <b>for</b> the <b>treatment</b> <b>of</b> colon cancer.|$|R
50|$|Stimulants are {{the most}} {{effective}} medications available <b>for</b> the <b>treatment</b> <b>of</b> ADHD. Seven different formulations of stimulants have {{been approved by the}} U.S. Food and Drug Administration (FDA) <b>for</b> the <b>treatment</b> <b>of</b> ADHD: four amphetamine-based formulations, two methylphenidate-based formulations, and dextromethamphetamine hydrochloride. Atomoxetine, guanfacine and clonidine are the only non-controlled, non-stimulant FDA approved drugs <b>for</b> the <b>treatment</b> <b>of</b> ADHD.|$|R
